Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.78 |
| ▸ | CSF1R | P07333 | 1/20 | 0.76 |
| ▸ | KIT | P10721 | 3/20 | 0.68 |
| ▸ | RAF1 | P04049 | 1/20 | 0.68 |
| ▸ | MET | P08581 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 1/20 | 0.68 |
| ▸ | FLT1 | P17948 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | BRAF | P15056 | 3/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7480612 | 0.88 | KDR (1.00) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5202999 | 0.88 | KDR (0.76) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL24358871 | 0.87 | KDR (0.85) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5202980 | 0.85 | KDR (0.85) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL6009208 | 0.85 | KDR (0.83) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5207985 | 0.84 | KDR (0.81) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5824362 | 0.84 | KDR (0.81) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5825524 | 0.83 | KDR (0.78) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5206337 | 0.82 | KDR (0.84) | KDRPDGFRACSF1RKITRAF1 | |
| SCHEMBL5204091 | 0.82 | KDR (0.89) | KDRPDGFRACSF1RKITRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125790-A1 | MULTI-TARGET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD FOR MULTI-TARGET KINASE INHIBITOR AND USE THEREOF | GUANGZHOU LIUSHUN BIOTECHNOLOGY CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3929182-A1 | MULTI-TARGET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | Guangzhou Liushun Biotechnology Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| WO-2020186812-A1 | MULTI-TARGET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | 广州六顺生物科技股份有限公司 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125790-A1 | MULTI-TARGET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD FOR MULTI-TARGET KINASE INHIBITOR AND USE THEREOF | RET, FLT4, KDR | KDR 3/4885PDGFRA 5/4885CSF1R 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.